Sponsors

• 

  Baxter BioPharma Solutions Program Partner BioPharma Solutions, a business unit of Baxter, offers clinical through commercial scale sterile manufacturing solutions and customized services to support your commercialization objectives. Highly Potent Active Pharmaceutical Ingredient (HPAPIs or HPAIs) compounds including Cytotoxics and Antibody-Drug Conjugates (ADCs) present many challenges due to the complex handling required for toxic substances. www.baxterbiopharmasolutions.com Read more...

• 

  Lonza Program Partner For over 25 years, Lonza has been helping emerging biotech and pharmaceutical companies improve and advance their products. Whether you are in the early stages of clinical development or providing commercial product to patients around the globe, Lonza supplies complete development services, industry-leading manufacturing, and broad technology platforms that enable products to reach their full potential. http://www.lonza.com Read more...

• 

  Piramal Healthcare Program Partner Piramal Healthcare’s Antibody Drug Conjugate Business is one of the world’s leading contract developmentand manufacturing teams delivering early phase clinical and late phase commercial supplies. Our flexiblemanufacturing regime and dedication to ADC processing is why our clients choose Piramal Healthcareas their preferred partner. www.piramalpharmasolutions.com Read more...

• 

  Quanta Biosciences Program Partner Quanta BioDesign, Ltd. was founded for the purpose of developing a line of products involved in drug discovery and diagnostic development. Over the past 30 years the PEGylation of biologics has been completely defined by the use of generally high MW and highly polydispersed PEGs. work.quantabio.com Read more...

• 

  SAFC Program Partner SAFC is a leading contract manufacturer for the pharmaceutical and biopharmaceutical industry, specialized in high-value complex technologies including virus manufacturing, high potent APIs, potent fermentation and antibody drug conjugates. www.safcglobal.com Read more...

• 

  Viventia Viventia Biotechnologies Viventia Biotechnologies Inc. is a privately held biopharmaceutical company specializing in the discovery and development of a new generation of immunotoxin products offering safer and more beneficial cancer therapies. Viventia is employing its novel human antibody and target discovery platform and its proprietary payload, De-Bouganin, to create a portfolio of new antibody products directed at proprietary oncology drug targets. http://www.viventia.com/